Biohaven Presents Three Posters on Graves’ Disease at ATA Meeting
Biohaven said it presented three posters at the 2026 American Thyroid Association meeting. The headline also says a Phase 3 pivotal trial of BHV-1300 is underway.
Story updates
12:32:50 PM UTC
SquawkNews
Biohaven said its pivotal Phase 3 trial of BHV-1300 in Graves' disease is actively enrolling, with m